Lumasiran targets primary hyperoxaluria type 1 (PH1), which affects just around 90 people in the UK and one to three individuals per million in EuropeOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.